Summary
JNJ recently increased its full-year 2018 guidance and expects EPS to increase at least 8.5% compared to 2017.
JNJ's dividend has increased for over 50 years in row, putting it in a rare club of stocks that have become aristocrats two times over.
Pfizer trades at a cheaper valuation, but JNJ's recent performance and recession resistance make its premium reasonable.
Johnson & Johnson (JNJ) and Pfizer (PFE) have long been two of my favorite dividend stocks. You really can't go wrong with either. Each is a reliable performer and reasonably valued. With that being said, I give JNJ the slight edge for the following reasons:
